Table 1 Clinical characteristics of the cohort
Clinical characteristics | Men | Women | P value | |
|---|---|---|---|---|
Median age (mean) | 75 (76.5) | 75 (76.5) | ||
Hypertension (%) | 1037 (67.2) | 282 (50.3) | < 0.001 | |
Diabetes mellitus (%) | 422 (28.2) | 70 (12.5) | < 0.001 | |
Dyslipidemia (%) | 1187 (79.2) | 418 (74.5) | 0.021 | |
Smoking* (past/active) (%) | 811 (54.1) | 230 (41.0) | < 0.001 | |
Ischemic heart disease (%) | 466 (31.1) | 24 (4.3) | < 0.001 | |
Stroke (%) | 61 (4.1) | 14 (2.5) | 0.089 | |
Cognitive decline (%) | 88 (5.8) | 35 (6.2) | 0.756 | |
Obstructive lung disease (%) | 37 (2.5) | 8 (1.4) | 0.149 | |
Chronic renal failure (%) | 368 (24.6) | 53 (9.5) | < 0.001 | |
Atrial fibrillation (%) | 165 (11.0) | 33 (5.9) | < 0.001 | |
Solid malignancy (%) | 372 (24.9) | 124 (22.1) | 0.192 | |
Hematological malignancy (%) | 75 (5.0) | 23 (4.1) | 0.386 | |
Any malignancy (%) | 429 (28.6) | 139 (24.8) | 0.081 | |
Colonic polypectomy (%) | 597 (39.9) | 164 (29.2) | < 0.001 | |
Lipid lowering drug use > 3 years (%) | 1077 (71.9) | 344 (61.3) | < 0.001 | |
Anti-platelet therapy (%) | 772 (49.7) | 140 (24.9) | < 0.001 | |
Anti-coagulant therapy (%) | 173 (11.6) | 35 (6.2) | < 0.001 | |
Death (%) | 46 (3.1) | 5 (0.9) | 0.005 |